1. Cooper BA, Branley P, Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 2010;363:609–619.
2. Collins J, Cooper B, Branley P, et al. Outcomes of patients with planned initiation of hemodialysis in the IDEAL trial. Contrib Nephrol 2011;171:1–9.
3. Harris A, Cooper BA, Li JJ, et al. Cost-effectiveness of initiating dialysis early: a randomized controlled trial. Am J Kidney Dis 2011;57:707–715.
4. Whalley GA, Marwick TH, Doughty RN, et al. Effect of early initiation of dialysis on cardiac structure and function: results from the echo substudy of the IDEAL trial. Am J Kidney Dis 2013;61:262–270.
5. Korevaar JC, Jansen MA, Dekker FW, et al. When to initiate dialysis: effect of proposed US guidelines on survival. Lancet 2001;358:1046–1050.
6. Traynor JP, Simpson K, Geddes CC, Deighan CJ, Fox JG. Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. J Am Soc Nephrol 2002;13:2125–2132.
7. Kazmi WH, Gilbertson DT, Obrador GT, et al. Effect of comorbidity on the increased mortality associated with early initiation of dialysis. Am J Kidney Dis 2005;46:887–896.
8. Hwang SJ, Yang WC, Lin MY, Mau LW, Chen HC, Taiwan Society of Nephrology. Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan. Nephrol Dial Transplant 2010;25:2616–2624.
9. Lassalle M, Labeeuw M, Frimat L, et al. Age and comorbidity may explain the paradoxical association of an early dialysis start with poor survival. Kidney Int 2010;77:700–707.
19. Lok CE, Huber TS, Lee T, et al. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis 2020;75(4 Suppl 2):S1–S164.
20. Shechter SM, Skandari MR, Zalunardo N. Timing of arteriovenous fistula creation in patients with CKD: a decision analysis. Am J Kidney Dis 2014;63:95–103.
22. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med 1981;305:1176–1181.
25. Shinzato T, Nakai S, Akiba T, et al. Survival in long-term haemodialysis patients: results from the annual survey of the Japanese Society for Dialysis Therapy. Nephrol Dial Transplant 1997;12:884–888.
27. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001;38:85–90.
28. Charra B, Calemard M, Laurent G. Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. Am J Nephrol 1996;16:35–44.
29. Marshall MR, Byrne BG, Kerr PG, McDonald SP. Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients. Kidney Int 2006;69:1229–1236.
33. Held PJ, Port FK, Wolfe RA, et al. The dose of hemodialysis and patient mortality. Kidney Int 1996;50:550–556.
34. Bloembergen WE, Stannard DC, Port FK, et al. Relationship of dose of hemodialysis and cause-specific mortality. Kidney Int 1996;50:557–565.
35. Chertow GM, Owen WF, Lazarus JM, Lew NL, Lowrie EG. Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Kidney Int 1999;56:1872–1878.
36. Wolfe RA, Ashby VB, Daugirdas JT, Agodoa LY, Jones CA, Port FK. Body size, dose of hemodialysis, and mortality. Am J Kidney Dis 2000;35:80–88.
37. Port FK, Ashby VB, Dhingra RK, Roys EC, Wolfe RA. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 2002;13:1061–1066.
38. Salahudeen AK, Dykes P, May W. Risk factors for higher mortality at the highest levels of spKt/V in haemodialysis patients. Nephrol Dial Transplant 2003;18:1339–1344.
39. Termorshuizen F, Dekker FW, van Manen JG, et al. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004;15:1061–1070.
40. Port FK, Wolfe RA, Hulbert-Shearon TE, McCullough KP, Ashby VB, Held PJ. High dialysis dose is associated with lower mortality among women but not among men. Am J Kidney Dis 2004;43:1014–1023.
43. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010–2019.
46. Ayli M, Ayli D, Azak A, et al. The effect of high-flux hemodialysis on dialysis-associated amyloidosis. Ren Fail 2005;27:31–34.
48. Klemm A, Franke C, Busch M, et al. Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites. Clin Nephrol 2004;61:191–197.
49. Kuchle C, Fricke H, Held E, Schiffl H. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol 1996;16:484–488.
52. Locatelli F, Andrulli S, Pecchini F, et al. Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrol Dial Transplant 2000;15:1399–1409.
53. Locatelli F, Mastrangelo F, Redaelli B, et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996;50:1293–1302.
54. Simon P, Ang KS, Cam G, Benziane A, Bonn F. Indices of adequate dialysis in patients hemodialyzed with AN 69 membrane. Kidney Int Suppl 1993;41:S291–S295.
55. Ok E, Asci G, Toz H, et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant 2013;28:192–202.
56. Morena M, Jaussent A, Chalabi L, et al. Treatment tolerance and patient-reported outcomes favor online hemodiafiltration compared to high-flux hemodialysis in the elderly. Kidney Int 2017;91:1495–1509.
59. Kantartzi K, Panagoutsos S, Mourvati E, et al. Can dialysis modality influence quality of life in chronic hemodialysis patients?: low-flux hemodialysis versus high-flux hemodiafiltration: a cross-over study. Ren Fail 2013;35:216–221.
63. Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W. A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. J Am Soc Nephrol 2000;11:2344–2350.
66. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 2004;15:3192–3206.
70. Ryan KE, Lane DA, Flynn A, Shepperd J, Ireland HA, Curtis JR. Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis. Thromb Haemost 1991;66:277–282.
71. Al-Saran KA, Sabry A, Taha M, Ghafour MA, Al Fawzan F. Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis. Saudi J Kidney Dis Transpl 2010;21:43–49.
74. Sabry A, Taha M, Nada M, Al Fawzan F, Alsaran K. Anticoagulation therapy during haemodialysis: a comparative study between two heparin regimens. Blood Coagul Fibrinolysis 2009;20:57–62.
75. Bambauer R, Rucker S, Weber U, Kohler M. Comparison of low molecular weight heparin and standard heparin in hemodialysis. ASAIO Trans 1990;36:M646–M649.
77. Nurmohamed MT, ten Cate J, Stevens P, Hoek JA, Lins RL, ten Cate JW. Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients: a comparison with standard heparin. ASAIO Trans 1991;37:M459–M461.
78. Saltissi D, Morgan C, Westhuyzen J, Healy H. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transplant 1999;14:2698–2703.
79. Schrader J, Stibbe W, Armstrong VW, et al. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988;33:890–896.
81. Kim HC, Han SY, Kim HK, et al. A multi-center phase III clinical trial to assess the influence to bleeding and anticoagulant effect of Nafamostat Mesilate (Futhan) in hemodialysis patients with high bleeding-risk. Korean J Nephrol 2004;23:920–926.
82. Yang JW, Han BG, Kim BR, et al. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage. Ren Fail 2009;31:668–675.
85. Foley RN, Herzog CA, Collins AJ, United States Renal Data System. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002;62:1784–1790.
86. Saran R, Bragg-Gresham JL, Rayner HC, et al. Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int 2003;64:254–262.
88. Kurita N, Hayashino Y, Yamazaki S, et al. Revisiting interdialytic weight gain and mortality association with serum albumin interactions: the Japanese Dialysis Outcomes and Practice Pattern Study. J Ren Nutr 2017;27:421–429.
92. Wong MM, McCullough KP, Bieber BA, et al. Interdialytic weight gain: trends, predictors, and associated outcomes in the International Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2017;69:367–379.
94. Leggat JE Jr, Orzol SM, Hulbert-Shearon TE, et al. Noncompliance in hemodialysis: predictors and survival analysis. Am J Kidney Dis 1998;32:139–145.
96. Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992;41:1286–1291.
97. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001;12:2759–2767.
98. Mominadam S, Ozkahya M, Kayikcioglu M, et al. Interdialytic blood pressure obtained by ambulatory blood pressure measurement and left ventricular structure in hypertensive hemodialysis patients. Hemodial Int 2008;12:322–327.
100. Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007;298:1291–1299.
101. Katzarski KS, Charra B, Luik AJ, et al. Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant 1999;14:369–375.
103. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002;61:2235–2239.
104. Marshall MR, Dunlop JL. Are dialysate sodium levels too high? Semin Dial 2012;25:277–283.
105. Kim SM, Kim JG, Shin JH, et al. The effects of low sodium dialysate in hemodialysis patients. Korean J Nephrol 2011;30:53–60.
107. Beduschi GC, Telini LS, Caramori JC, Martin LC, Barretti P. Effect of dialysate sodium reduction on body water volume, blood pressure, and inflammatory markers in hemodialysis patients: a prospective randomized controlled study. Ren Fail 2013;35:742–747.
108. Boquin E, Parnell S, Grondin G, et al. Crossover study of the effects of different dialysate sodium concentrations in large surface area, short-term dialysis. Proc Clin Dial Transplant Forum 1977;7:48–52.
109. Liu J, Sun F, Ma LJ, Shen Y, Mei X, Zhou YL. Increasing dialysis sodium removal on arterial stiffness and left ventricular hypertrophy in hemodialysis patients. J Ren Nutr 2016;26:38–44.
112. Kooman JP, Hendriks EJ, van Den Sande FM, Leumissen KM. Dialysate sodium concentration and blood pressure control in haemodialysis patients. Nephrol Dial Transplant 2000;15:554.
113. Sayarlioglu H, Erkoc R, Tuncer M, et al. Effects of low sodium dialysate in chronic hemodialysis patients: an echocardiographic study. Ren Fail 2007;29:143–146.
116. Hannedouche T, Roth H, Krummel T, et al. Multiphasic effects of blood pressure on survival in hemodialysis patients. Kidney Int 2016;90:674–684.
123. Selby NM, Burton JO, Chesterton LJ, McIntyre CW. Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate. Clin J Am Soc Nephrol 2006;1:1216–1225.
124. Chesterton LJ, Selby NM, Burton JO, McIntyre CW. Cool dialysate reduces asymptomatic intradialytic hypotension and increases baroreflex variability. Hemodial Int 2009;13:189–196.
125. Fine A, Penner B. The protective effect of cool dialysate is dependent on patients’ predialysis temperature. Am J Kidney Dis 1996;28:262–265.
126. Jost CM, Agarwal R, Khair-el-Din T, Grayburn PA, Victor RG, Henrich WL. Effects of cooler temperature dialysate on hemodynamic stability in “problem” dialysis patients. Kidney Int 1993;44:606–612.
127. Ayoub A, Finlayson M. Effect of cool temperature dialysate on the quality and patients’ perception of haemodialysis. Nephrol Dial Transplant 2004;19:190–194.
128. Maggiore Q, Pizzarelli F, Santoro A, et al. The effects of control of thermal balance on vascular stability in hemodialysis patients: results of the European randomized clinical trial. Am J Kidney Dis 2002;40:280–290.
130. Cruz DN, Mahnensmith RL, Brickel HM, Perazella MA. Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension. Am J Kidney Dis 1999;33:920–926.
131. Azar AT. Effect of dialysate temperature on hemodynamic stability among hemodialysis patients. Saudi J Kidney Dis Transpl 2009;20:596–603.
133. Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993;329:1001–1006.
134. Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994;23:661–669.
135. Parker TF 3rd, Husni L, Huang W, Lew N, Lowrie EG. Survival of hemodialysis patients in the United States is improved with a greater quantity of dialysis. Am J Kidney Dis 1994;23:670–680.
136. Collins AJ, Ma JZ, Umen A, Keshaviah P. Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis 1994;23:272–282.
137. Thomas A, Silver SA, Perl J, et al. The frequency of routine blood sampling and patient outcomes among maintenance hemodialysis recipients. Am J Kidney Dis 2020;75:471–479.
138. Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006;48:Suppl 1. S2–S90.
139. Tattersall J, Martin-Malo A, Pedrini L, et al. EBPG guideline on dialysis strategies. Nephrol Dial Transplant 2007;22(Suppl 2):ii5–ii21.
140. Drueke TB, Parfrey PS. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int 2012;82:952–960.
141. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1–S130.
146. Foote C, Kotwal S, Gallagher M, Cass A, Brown M, Jardine M. Survival outcomes of supportive care versus dialysis therapies for elderly patients with end-stage kidney disease: a systematic review and meta-analysis. Nephrology (Carlton) 2016;21:241–253.
149. Joly D, Anglicheau D, Alberti C, et al. Octogenarians reaching end-stage renal disease: cohort study of decision-making and clinical outcomes. J Am Soc Nephrol 2003;14:1012–1021.
150. Murtagh FE, Marsh JE, Donohoe P, Ekbal NJ, Sheerin NS, Harris FE. Dialysis or not?: a comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dial Transplant 2007;22:1955–1962.
157. Tam-Tham H, Quinn RR, Weaver RG, et al. Survival among older adults with kidney failure is better in the first three years with chronic dialysis treatment than not. Kidney Int 2018;94:582–588.
160. Kaur A, Davenport A. Hemodialysis for infants, children, and adolescents. Hemodial Int 2014;18:573–582.
161. Chand DH, Swartz S, Tuchman S, Valentini RP, Somers MJ. Dialysis in children and adolescents: the pediatric nephrology perspective. Am J Kidney Dis 2017;69:278–286.
162. Salerno AE, Weinstein A, Hanevold C. American Society of Pediatric Nephrology Position Paper: standard resources required for a pediatric nephrology practice. J Pediatr 2016;174:254–259.
163. Jones L, Aldridge M. Organization and management of a pediatric dialysis program. In: Warady BA, Schaefer F, Alexander SR, eds. Pediatric Dialysis. New York (NY): Springer, 2012;53–72.
164. Royal College of Nursing (Great Britain); British Renal Society, Renal Association (Great Britain). The Renal Team. A Multi-Professional Renal Workforce Plan for Adults and Children with Renal Disease. Bristol (UK): British Renal Society, 2002.